--- title: "Nasus Pharma (NSRX) news: going concern, IPO and offering" url: "https://aibio.space/companies/nasus-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NSRX going concern, IPO and offering news: Nasus Pharma sets up at-the-market program with BTIG for up to $8,500,000 of shares. Nasus Pharma Ltd." --- NSRX Nasus Pharma Ltd. AMEX · Israel # Nasus Pharma (NSRX) news NSRX going concern, IPO and offering news Financings · 2026-09-18 ## [Nasus Pharma sets up at-the-market program with BTIG for up to $8,500,000 of shares](https://aibio.space/news/nasus-pharma-sets-up-market-program-btig-up-8-500-000-shares/) Nasus Pharma can sell up to $8,500,000 of shares through BTIG but is not obliged to. Its June 30, 2026 balance sheet held $11,904 thousand in cash, restricted cash and short-term deposits, and its prospectus supplement lists substantial doubt about going concern among its risks. ## Latest Nasus Pharma news 1. 2025-07-09 Financings [Nasus Pharma files for 1,000,000-share NYSE American IPO, expects $10.00 to $12.00](https://aibio.space/news/nasus-pharma-files-1-000-000-share-nyse-american-ipo-expects-10-00-12/) Nasus Pharma seeks to list 1,000,000 shares on NYSE American at $10.00 to $12.00. Its prospectus says current cash will not fund planned operations, which raises substantial doubt about going concern, and its epinephrine Phase 2 study included 12 patients. ## Nasus Pharma at a glance - **Ticker**: NSRX - **Listing**: AMEX - **Country**: Israel - **Cash, Dec 31, 2025**: $1.2 million ### Related companies - [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX - [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL - [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD - [Can-Fite BioPharma](https://aibio.space/companies/can-fite-biopharma/) TASE: CANF - [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT - [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL - [Eocene](https://aibio.space/companies/eocene/) NASDAQ: EOCN - [Entera Bio](https://aibio.space/companies/entera-bio/) NASDAQ: ENTX ### Also on AMEX - [Perspective Therapeutics](https://aibio.space/companies/perspective-therapeutics/) CATX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) PTHS - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP ## Nasus Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.24 billion](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | | | Research and development | [$2.2 million](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | [$335,000](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | | Net income (loss) | [-$5.9 million](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | [-$1.5 million](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | | Cash from operations | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | [-$665,000](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | | Cash and equivalents | [$1.2 million](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | [$284,000](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nasus Pharma Has Nasus Pharma issued a going-concern warning? Our latest story on this, dated Sep 18, 2026: "Nasus Pharma sets up at-the-market program with BTIG for up to $8,500,000 of shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasus-pharma-sets-up-market-program-btig-up-8-500-000-shares/). When did Nasus Pharma go public? Our latest story on this, dated Jul 9, 2025: "Nasus Pharma files for 1,000,000-share NYSE American IPO, expects $10.00 to $12.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasus-pharma-files-1-000-000-share-nyse-american-ipo-expects-10-00-12/). Has Nasus Pharma raised money recently? Our latest story on this, dated Sep 18, 2026: "Nasus Pharma sets up at-the-market program with BTIG for up to $8,500,000 of shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasus-pharma-sets-up-market-program-btig-up-8-500-000-shares/). What is the ticker symbol of Nasus Pharma? Nasus Pharma Ltd. trades under the ticker NSRX on AMEX. Where is Nasus Pharma listed? Nasus Pharma Ltd. is listed on AMEX. What is the SEC CIK of Nasus Pharma? The SEC Central Index Key (CIK) for Nasus Pharma Ltd. is 2029039. Its filings are on SEC EDGAR. How many shares does Nasus Pharma have outstanding? 9,015,383 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-25. Which country or territory is Nasus Pharma listed under? Our directory records Nasus Pharma Ltd. under Israel. What does Nasus Pharma do? Our directory classifies Nasus Pharma Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Nasus Pharma? The ISIN recorded for Nasus Pharma Ltd. is IL0012181553. Does aibio.space cover Nasus Pharma? aibio.space lists Nasus Pharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nasus Pharma incorporated? SEC records list its state or country of incorporation as L3. What was Nasus Pharma's revenue last year? $1.24 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Nasus Pharma profitable? Nasus Pharma Ltd. reported a net loss of $5.9 million for the fiscal year ended Dec 31, 2025, and used $4.9 million of cash in operations, per its annual report to the SEC. How much does Nasus Pharma spend on research and development? $2.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Nasus Pharma Members talk about Nasus Pharma (NSRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nasus Pharma, newest first. Each line links the filing it comes from. 1. 2026-09-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315226043342/form6-k.htm) 2. 2026-03-25 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/form20-f.htm) 3. 2026-03-25 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315226012663/ex99-1.htm) 4. 2026-02-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315226006265/ex99-1.htm) 5. 2025-12-22 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315225028664/ex99-1.htm) 6. 2025-08-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000149315225011984/ex99-1.htm) 7. 2025-07-09 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/2029039/000164117225018388/formf-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:NSRX on TradingView](https://www.tradingview.com/symbols/AMEX-NSRX/). ## SEC filings and registration - **SEC name**: Nasus Pharma Ltd - **CIK**: 2029039 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NSRX (NYSE) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 29 HARAKEVET ST, TEL AVIV - YAFO, Israel, 6618003 - **Phone**: 972 54-255-3956 - **Shares outstanding**: 9,015,383 as of 2025-12-31 (20-F filed 2026-03-25) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226046340/form6-k.htm) filed 2026-10-08 - [424B5](https://www.sec.gov/Archives/edgar/data/2029039/000149315226043370/form424b5.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226043342/form6-k.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226042488/form6-k.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226041534/form6-k.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226039148/form6-k.htm) filed 2026-08-19 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226038651/form6-k.htm) filed 2026-08-17 - [6-K](https://www.sec.gov/Archives/edgar/data/2029039/000149315226034938/form6-k.htm) filed 2026-07-28 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002029039), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nasus Pharma Ltd. is a public biotech or pharmaceutical company listed on AMEX under the ticker NSRX, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nasus Pharma Ltd. - **Ticker**: NSRX - **Listing**: AMEX - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: IL0012181553 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-NSRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nasus-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nasus Pharma (NSRX) news: going concern, IPO and offering", 2026-10-31, https://aibio.space/companies/nasus-pharma/